Clinical Trials Logo
  1. Home
  2. Overactive Bladder Syndrome
  3. NCT01627145
  4. Details
NCT01627145 Clinical Trial

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

Overactive Bladder Syndrome Clinical Trial

Official title:
Post-treatment Normallized Urodynamic Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Correlations With Voiding Diary, Kingļ¼‡s Health Questionnaire, and Overactive Bladder Sympto

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01627145
Other study ID # 201012024RC
Secondary ID
Status Recruiting
Phase N/A
First received June 21, 2012
Last updated November 14, 2012
Start date August 2012
Est. completion date July 2015

Study information
Verified date November 2012
Source National Taiwan University Hospital
Contact Ho-Hsiung Lin, PhD
Phone +886-2-23123456
Email hhlin@ntuh.gov.tw
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Interventional

Clinical Trial Summary

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Conelations With Voiding Diary, King's Health Quentionaire, Overactive Bladder Sympton Scores and Patient Perception of Bladder Condition.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date July 2015
Est. primary completion date January 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- female patients within 18 years old to 99 years old with overactive bladder syndrome

Exclusion Criteria:

- unwilling or unable to perform testing procedure

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Solifenacin
Solifenacin 5 mg qd,

Locations
Country Name City State
Taiwan No 8, Chung-Shan South Road, Taipei

Sponsors (1)
Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome
Type Measure Description Time frame Safety issue
Primary The percentage of normalized urodynamic pattern after treatment 12 weeks No
Secondary The percentage of recurrence rates after treatment during follow-up and further to analyze the risk factors of recurrence 48 months No
See also
  Status Clinical Trial Phase
Completed NCT02540707 - Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Phase 4
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Not yet recruiting NCT06438861 - Role of Combination Therapy in Women With Refractory Overactive Bladder N/A
Completed NCT01114412 - Basic Sensations Coming From the Bladder
Recruiting NCT06045728 - Telerehabilitation for Overactive Bladder Syndrome in Obese Women N/A
Recruiting NCT03952299 - Oxybutynin for Post-surgical Bladder Pain and Urgency Phase 3
Active, not recruiting NCT03758235 - Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin Phase 3
Completed NCT01912885 - Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome N/A
Completed NCT04300400 - Treatment of the Overactive Bladder Syndrome: A Delphi Study
Recruiting NCT04982120 - Use of Repris Needle in Bladder Injection N/A
Completed NCT06123364 - Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder N/A
Recruiting NCT06088394 - Effect of Acupuncture Augmented With Pelvic Floor Exercises on Overactive Bladder N/A
Recruiting NCT05221021 - Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome Phase 4
Terminated NCT04256876 - TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) N/A
Not yet recruiting NCT03331081 - Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome N/A
Recruiting NCT04873037 - BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder N/A
Completed NCT02024945 - Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome Phase 4
Completed NCT00546637 - Fesoterodine "add-on" Male Overactive Bladder Study Phase 3
Not yet recruiting NCT06143397 - Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis. N/A
Recruiting NCT03044912 - Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan Phase 3